{"title":"Gut microbiota and Alzheimer's disease: Exploring natural product intervention and the Gut–Brain axis for therapeutic strategies","authors":"","doi":"10.1016/j.ejphar.2024.177022","DOIUrl":null,"url":null,"abstract":"<div><div>Numerous studies conducted over the last ten years have shown a strong correlation between the gut microbiota and the onset and progression of Alzheimer's disease (AD). However, the exact underlying mechanism is still unknown. An ongoing communication mechanism linking the gut and the brain is highlighted by the term “microbiota–gut–brain axis,” which was originally coined the “gut–brain axis.” Key metabolic, endocrine, neurological, and immunological mechanisms are involved in the microbiota‒gut‒brain axis and are essential for preserving brain homeostasis. Thus, the main emphasis of this review is how the gut microbiota contributes to the development of AD and how various natural products intervene in this disease. The first part of the review provides an outline of various pathways and relationships between the brain and gut microbiota, and the second part provides various mechanisms involved in the gut microbiota and AD. Finally, this review provides knowledge about natural products and their effectiveness in treating gut microbiota-induced AD. AD may be treated in the future by altering the gut microbiota with a customized diet, probiotics/prebiotics, plant products, and natural products. This entails altering the microbiological partners and products (such as amyloid protein) that these partners generate.</div></div>","PeriodicalId":12004,"journal":{"name":"European journal of pharmacology","volume":null,"pages":null},"PeriodicalIF":4.2000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of pharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S001429992400712X","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Numerous studies conducted over the last ten years have shown a strong correlation between the gut microbiota and the onset and progression of Alzheimer's disease (AD). However, the exact underlying mechanism is still unknown. An ongoing communication mechanism linking the gut and the brain is highlighted by the term “microbiota–gut–brain axis,” which was originally coined the “gut–brain axis.” Key metabolic, endocrine, neurological, and immunological mechanisms are involved in the microbiota‒gut‒brain axis and are essential for preserving brain homeostasis. Thus, the main emphasis of this review is how the gut microbiota contributes to the development of AD and how various natural products intervene in this disease. The first part of the review provides an outline of various pathways and relationships between the brain and gut microbiota, and the second part provides various mechanisms involved in the gut microbiota and AD. Finally, this review provides knowledge about natural products and their effectiveness in treating gut microbiota-induced AD. AD may be treated in the future by altering the gut microbiota with a customized diet, probiotics/prebiotics, plant products, and natural products. This entails altering the microbiological partners and products (such as amyloid protein) that these partners generate.
过去十年间进行的大量研究表明,肠道微生物群与阿尔茨海默病(AD)的发病和进展之间存在密切联系。然而,确切的内在机制仍然未知。"微生物群-肠道-大脑轴"(最初被称为 "肠道-大脑轴")一词强调了连接肠道和大脑的持续沟通机制。微生物群-肠-脑轴涉及关键的新陈代谢、内分泌、神经和免疫机制,对维持大脑平衡至关重要。因此,这篇综述的重点是肠道微生物群如何导致注意力缺失症的发展,以及各种天然产品如何干预这种疾病。综述的第一部分概述了大脑与肠道微生物群之间的各种途径和关系,第二部分介绍了肠道微生物群与 AD 的各种相关机制。最后,本综述介绍了天然产品及其在治疗肠道微生物诱导的注意力缺失症方面的有效性。未来可通过定制饮食、益生菌/益生元、植物产品和天然产品改变肠道微生物群来治疗注意力缺失症。这需要改变微生物伙伴和这些伙伴产生的产物(如淀粉样蛋白)。
期刊介绍:
The European Journal of Pharmacology publishes research papers covering all aspects of experimental pharmacology with focus on the mechanism of action of structurally identified compounds affecting biological systems.
The scope includes:
Behavioural pharmacology
Neuropharmacology and analgesia
Cardiovascular pharmacology
Pulmonary, gastrointestinal and urogenital pharmacology
Endocrine pharmacology
Immunopharmacology and inflammation
Molecular and cellular pharmacology
Regenerative pharmacology
Biologicals and biotherapeutics
Translational pharmacology
Nutriceutical pharmacology.